Hikma Pharmaceuticals PLC (LSE:HIK)
£ 18.31 0.3 (1.67%) Market Cap: 4.06 Bil Enterprise Value: 4.80 Bil PE Ratio: 27.57 PB Ratio: 2.36 GF Score: 90/100

Half Year 2021 Hikma Pharmaceuticals PLC Earnings Call (Q&A Session) Transcript

Aug 06, 2021 / 08:30AM GMT
Release Date Price: £24.55 (-7.08%)
Layan Kalisse

Okay. It looks like we have everyone in the room, and we're ready to kick off.

Sigurdur Oli Olafsson
Hikma Pharmaceuticals PLC - CEO & Executive Director

Thanks, Layan. So we're ready to go. I thought we would just open it straight up for questions and answers. So if you have a question, let us know, and we'd be happy to kick it off.

Questions & Answers

Layan Kalisse

So this is just going to be the usual setup. (Operator Instructions)

So we already have our first question from Pete Verdult.

Peter Verdult
Citigroup Inc., Research Division - MD

Yes. Peter Verdult, Citi. Two questions. Just firstly, maybe just starting with Branded actually. Great start to the year. You're still saying mid-single-digit growth basically means that you're going to be declining in the second half. I know you talked about some pull-through, but can you just help us understand, is there any sort of upside risks growing Branded versus the guidance, not just near term,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot